课题基金 / 基金详情

项目摘要

项目成果

STEPHANIE TEAL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The NICHD's Contraceptive Clinical Trials network conducts Phase I, II and III clinical trials of a wide variety of new female and male contraceptive methods. The objective of this contract is for CCTN contractors to conduct female contraceptive clinical trials, conduct treatment trials of gynecologic conditions, and to develop research protocols on a task Order basis under an Indefinite Delivery/Indefinite Quantity (IDIQ) contract. There is a demand for new methods of contraception that can provide effective protection against unintended pregnancy as well as reduce the risk of venous thromboembolism (VTE), particularly for obese women. A new vaginal ring that can deliver a high dose progestin (Nestorone) and a low dose of estradiol (E2) may provide effective and safe contraception for women. The objective of the dose finding study is to identify a dose that can provide reliable contraception and acceptable bleeding patterns for up to 6 months of useThe proposed study will evaluate contraceptive efficacy , pharmacokinetics, bleeding patterns and safety and side effects of a Nestorone & estradiol ring for women.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CONTRACEPTIVE CLINICAL TRIALS NETWORK, CCTN - FEMALE SITES 'CORE FUNCTION ACTIVITIES
  • 批准号:
    10891325
  • 项目类别:
  • 资助金额:
    $0.17万
  • 财政年份:
    2023
  • 负责人:
    STEPHANIE TEAL
  • 依托单位:
CONTRACEPTIVE CLINICAL TRIALS NETWORK, CCTN - FEMALE SITES 'CORE FUNCTION ACTIVITIES
  • 批准号:
    10245991
  • 项目类别:
  • 资助金额:
    $1.18万
  • 财政年份:
    2020
  • 负责人:
    STEPHANIE TEAL
  • 依托单位:
CCTN-PHARMACOKINETIC / PHARMACODYNAMIC EVALUATION OF LEVONOGESTREL BUTANOATE FOR FEMALE CONTRACEPTION
  • 批准号:
    9795853
  • 项目类别:
  • 资助金额:
    $21.4万
  • 财政年份:
    2018
  • 负责人:
    STEPHANIE TEAL
  • 依托单位:
CCTN-PHARMACOKINETIC / PHARMACODYNAMIC EVALUATION OF LEVONOGESTREL BUTANOATE FOR FEMALE CONTRACEPTION
  • 批准号:
    10936500
  • 项目类别:
  • 资助金额:
    $6.59万
  • 财政年份:
    2018
  • 负责人:
    STEPHANIE TEAL
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: